Severe risk of uninfected “2 in a 1,000” dengue vaccine -Sanofi


LONDON, Dec 5 (Reuters) – French pharmaceutical company Sanofi said on Tuesday that the risk of severe dengue in previously uninfected people who received their Dengvaxia vaccine against dengue was around two in 1,000 and that these individuals recovered. With treatment.

The vaccine is at the center of a safety row after new data showed that dengue could worsen in some cases, prompting the Philippines to stop its sale and suspend a government program to immunize hundreds of thousands of people. children.

Responding to criticism of delays in reporting problems, Sanofi said he had only been able to conduct a detailed badysis to determine the impact of the dengue infection earlier this year, after jointly developing a new trial with the University of Pittsburgh.

"The increased risk identified by the new badysis resulted in two additional cases of 'severe dengue' of 1,000 people previously not infected with dengue vaccinated during five years of follow-up," the company said in a statement. Statement sent by email.

"In this group, everyone recovered completely with the proper medical treatment." (Information from Ben Hirschler)

Our standards: The principles of trust of Thomson Reuters.
Source link

Leave a Reply

Your email address will not be published.